## Edgar Filing: Hamel Lawrence G - Form 4/A

Form 4/A										
March 09, 20	Л					~~~				PPROVAL
	UNITEI	) STATES		ITIES A hington,			NGE (	COMMISSION	OMB Number:	3235-0287
Check this if no long subject to Section 10 Form 4 or	F CHAN	GES IN I SECUR		CIA	LOW	NERSHIP OF	Expires: Estimated a burden hou response	rs per		
Form 5 obligation may conti <i>See</i> Instru 1(b).	$\frac{1}{1}$ Section 17	7(a) of the		ility Hold	ling Com	ipany	Act of	e Act of 1934, f 1935 or Sectio 40	n	
(Print or Type R	esponses)									
			2. Issuer Name <b>and</b> Ticker or Trading Symbol ACELRX PHARMACEUTICALS					5. Relationship of Reporting Person(s) to Issuer		
			INC [AC	CRX]				(Chec	k all applicable	2)
(Last) C/O ACELR PHARMAC CHESAPEA	EUTICALS, IN	(Middle) NC., 575	3. Date of (Month/D 03/02/20	-	ansaction			Director X Officer (give below) Chief De		
Filed(Mon 03/06/20			mendment, Date Original /Ionth/Day/Year) /2012				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
	CITY, CA 94							Person		porting
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Acc	uired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	r) Execution any		Code (Instr. 8)	4. Securi on(A) or Di (D) (Instr. 3,	ispose	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	
Common Stock	03/02/2012			F	1,540 (1) (2)	D	\$ 2.91	13,820	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amou Unde Secur	le and unt of rlying rities (1, 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
Repo	rting O	wners	Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: Hamel Lawrence G - Form 4/A

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
Hamel Lawrence G C/O ACELRX PHARMACEUTICALS, INC. 575 CHESAPEAKE DRIVE REDWOOD CITY, CA 94063			Chief Development Officer			
Signatures						

/s/ James Welch,	03/09/20		
Attorney-in-fact	03/09/2012		

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares were withheld to satisfy tax liability upon vesting 25% of the restricted shares of Common Stock of the Company, previously reported on March 4, 2011.
- (2) The amendment corrects the incorrect amount of shares reported on the Form 4 filed on March 6, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.